A Message from Dr. Frank McCormick

| October 7, 2017 | 0 Comments
A Message from Dr. Frank McCormick

Frank McCormick, pioneering RAS researcher and former head of the UCSF cancer center, describes the problem with RAS cancers and how the NCI RAS Initiative will attack them.
See Original Article

What Do We Mean By "RAS Pathway"?

Frank McCormick, scientific lead of the RAS Initiative, requests input from the RAS community to update our conception of the “RAS pathway”.
See Original Article

Faint Light at the End of the Tunnel

Many cancers are dependent on an overactive MAPK pathway. While progress in inhibiting mutant RAS proteins is still in its early phase, third-generation drugs that inhibit the next protein in the pathway, RAF, are being tested. Gideon Bollag of Plexxikon describes some of the challenges of developing inhibitors of RAF.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply